No connection

Search Results

ISPC

BEARISH
$0.13 Live
iSpecimen Inc. · NASDAQ
$0.13 52W Range $3.18

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 12, 2026
Market cap
$3.8M
P/E
N/A
ROE
-327.8%
Profit margin
N/A
Debt/Equity
0.09
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
The company is in severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a total absence of a viable Altman Z-Score. Revenue has collapsed by 96.50% year-over-year, while operating margins have plummeted to -5192.87%, indicating a complete breakdown of the business model. With a 5-year price decline of 99.9% and a technical trend score of 0/100, the stock is in a terminal bearish phase. Despite a low debt-to-equity ratio, the lack of top-line growth and extreme losses make the equity highly speculative and high-risk.

Key Strengths

Low Debt/Equity ratio (0.09) suggests minimal long-term debt burden
Current Ratio of 1.12 indicates marginal short-term liquidity
Trading at a discount to book value (P/B 0.41)
Recent quarterly EPS beat estimates despite remaining negative
Operates in the high-demand Healthcare Diagnostics sector

Key Risks

Catastrophic revenue decline of -96.50% YoY
Extreme operational inefficiency with -5192.87% operating margin
Severe financial instability indicated by Piotroski F-Score of 1/9
Total collapse of shareholder value (-99.9% over 5 years)
Lack of institutional analyst coverage and target price guidance

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
5
Weak
Value
15
Future
0
Past
0
Health
10
Dividend
0
AI Verdict
Critical Distress
Key drivers: Revenue collapse, Extreme operating losses, Piotroski F-Score 1/9, Terminal price trend
Confidence
95%
Value
15/100

P/B is the only positive metric, but it is likely a lagging indicator of eroding assets.

Positives
  • Low Price-to-Book (0.41)
Watchpoints
  • No Graham Number available
  • P/S ratio of 1.97 is high given the revenue collapse
Future
0/100

Growth rates are catastrophic and suggest a failing business model.

Positives
No standout positives identified.
Watchpoints
  • Revenue growth -96.50%
  • Q/Q Revenue growth -96.49%
Past
0/100

Historical price performance shows a total loss of investor confidence.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change -99.9%
  • 1Y Change -89.9%
Health
10/100

The Piotroski score confirms the company is in the weakest possible health bracket.

Positives
  • Low Debt/Equity
Watchpoints
  • Piotroski F-Score 1/9
  • ROE -327.77%
Dividend
0/100

Company is not in a position to return capital.

Positives
No standout positives identified.
Watchpoints
  • No dividend yield
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.13

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ISPC and closest competitors.

Updated 2026-04-10
ISP
iSpecimen Inc.
Primary
5Y
-99.9%
3Y
-99.5%
1Y
-89.9%
6M
-85.3%
1M
-46.7%
1W
-9.9%
ACO
Aclarion, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-82.0%
6M
-56.9%
1M
+22.9%
1W
+1.8%
JAG
Jaguar Health, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-92.8%
6M
-82.2%
1M
-34.7%
1W
-7.8%
HCT
Healthcare Triangle, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-99.9%
6M
-98.6%
1M
-21.6%
1W
-2.8%
INB
Intelligent Bio Solutions Inc.
Peer
5Y
-100.0%
3Y
-99.3%
1Y
-79.8%
6M
-77.0%
1M
-39.7%
1W
-10.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-0.16
PEG Ratio
N/A
P/B Ratio
0.41
P/S Ratio
1.97
EV/Revenue
-1.46
EV/EBITDA
0.32
Market Cap
$3.8M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -5192.87%
Gross Margin 1.25%
ROE -327.77%
ROA -59.44%

Growth

Revenue and earnings growth rates

Revenue Growth -96.5%
Earnings Growth N/A
Q/Q Revenue Growth -96.49%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.09
Low debt
Current Ratio
1.12
Good
Quick Ratio
1.11
Good
Cash/Share
$0.23

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
-1056.9%
Op. Margin
-5192.9%
Net Margin
-9662.2%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
2.09x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2024-08-06
$-3.8
+32.1% surprise
2024-05-07
$-6.4
-18.5% surprise
2024-03-13
$-6.8
-41.7% surprise
2023-11-02
$-4.6
+34.3% surprise

Healthcare Sector Comparison

Comparing ISPC against 264 companies in the Healthcare sector (20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-327.77%
This Stock
vs
-46.09%
Sector Avg
+611.2% (Excellent)
Debt to Equity
0.09
This Stock
vs
4.1
Sector Avg
-97.9% (Less Debt)
Revenue Growth
-96.5%
This Stock
vs
88.16%
Sector Avg
-209.5% (Slower)
Current Ratio
1.12
This Stock
vs
3.58
Sector Avg
-68.8% (Weaker)

Similar Companies

Peer comparison within the same industry

Past News Coverage

Recent headlines mentioning ISPC from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile